🇺🇸 FDA
Pipeline program

TYRA-300 0.125 mg/kg

TYR300-201

Phase 2 small_molecule active

Quick answer

TYRA-300 0.125 mg/kg for Achondroplasia is a Phase 2 program (small_molecule) at Tyra Biosciences with 1 ClinicalTrials.gov record(s).

Program details

Company
Tyra Biosciences
Indication
Achondroplasia
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials